Clinical trials: Poverty
Pulmonary Disease, Chronic Obstructive, Asthma
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD and known poor MDI inhalation technique following inhalation of Berodual delivered via the…
- Trial name
- NCT00267917
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Asthma
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
This is a research study designed to compare the single-dose efficacy of albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and albuterol-HFA-metered-dose inhaler (MDI) in asthmatics with poor inhaler coordinating…
- Trial name
- NCT00530062
- Testing
- Albuterol-HFA-MDI, Albuterol-HFA-BAI
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Diabetes Melliuts, Type 2
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
- Trial name
- NCT01673178
- Testing
- 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023
- Where
- 17 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Migraine With or Without Aura
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).
- Trial name
- NCT01989936
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg
- Where
- 43 sites in Denmark, Finland and 3 more
- Volunteers
- 446 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 1 Diabetes Mellitus
Effectiveness Study of the Guardian RT in Type 1 Diabetics
The purpose of this study is to determine whether Type 1 diabetic patients using the Guardian RT glucose sensor can improve glycemic control over a 12-week period, compared to patients using self-monitoring blood glucose testing…
- Trial name
- NCT01331343
- Testing
- Guardian RT Telemetered Glucose Monitoring System
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 156 people
- Sponsor
- Medtronic MiniMed, Inc.
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00383162
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium)
- Where
- 26 sites in United States
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.
- Trial name
- NCT01475851
- Testing
- GSK548470 300 mg tablet
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.
- Trial name
- NCT06649773
- Testing
- Noiiglutide Injection
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Subjects
A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers
To evaluate the pharmacokinetic (PK) profile of MIN-101 and its metabolites in extensive (EM) and poor (PM) metabolizers To evaluate the relationship between plasma levels of MIN-101 and changes in QT/QTcF intervals To evaluate…
- Trial name
- NCT03072056
- Testing
- MIN-101
- Where
- Ireland
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Minerva Neurosciences
Hyperlipidemia
Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Evaluation of the efficacy and safety of multiple subcutaneous injections of SHR-1918 in patients with hyperlipidemia in poor control: a multicenter, randomized, double-blind, placebo-controlled phase II clinical trials
- Trial name
- NCT06471218
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Healthy
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
The objective of the current study is to evaluate the effect of once daily itraconazole on the pharmacokinetics of BI 409306 in poor (PM) and extensive metabolisers (EM) of CYP2C19.
- Trial name
- NCT02248259
- Testing
- BI 409306, Itraconazole
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Smoking
Tobacco Quit Line Re-enrollments for the Underserved
The purpose of this proposed study is to develop, refine and test the use of Interactive Voice Response (IVR) technology as a means of increasing re-engagement of low income smokers in telephone support for tobacco cessation…
- Trial name
- NCT01260597
- Testing
- IVR intervention, IVR control
- Where
- United States
- Volunteers
- 2,985 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
HIV Infections
Reducing HIV Risks in African American Teens
This study is developing and testing an innovative, parent education intervention, Preparing Our Sons and Daughters for Healthy Futures.
- Trial name
- NCT00963963
- Testing
- Healthy Futures parent education
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Education Development Center, Inc.
Lung Cancer
Platelet-Rich and Concentrated Platelet-Poor Plasma to Reduce Air Leak Post-Lobectomy: A Randomized Controlled Trial
The purpose of this study is to determine whether the use of platelet-rich plasma (PRP) and concentrated platelet-poor plasma (PPPc) can reduce the duration of post-operative air leak after lobectomy for lung tumours.
- Trial name
- NCT00665912
- Testing
- Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively, Standard post-lobectomy wound care
- Where
- Canada
- Volunteers
- 204 people
- Sponsor
- Zimmer Biomet
Poor Quality Sleep
the Effect of Probiotic on Sleep Quality Management
The goal of this clinical trial is to learn about the improvement of sleep quality of probiotic BLa 80 in 110 healthy college students.
- Trial name
- NCT06107049
- Testing
- BLa80
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Schizophrenia
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in…
- Trial name
- CASPAR (NCT04940039)
- Testing
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq.
- Where
- 5 sites in Rwanda
- Volunteers
- 93 people
- Sponsor
- Janssen-Cilag International NV
Type 1 Diabetes
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive…
- Trial name
- RTD (NCT00441129)
- Testing
- Minimed paradigm Real Time Sytem, Minimed Paradigm 512/712 Insulin pump
- Where
- 8 sites in France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.